dsm-firmenich in the news

BNP Paribas downgraded DSM-Firmenich stock to Neutral with a EUR 100 price target, as the company reported mixed half-year results with strong revenue growth but weak cash conversion, despite completing a share repurchase.

A consortium including dsm-firmenich is testing a new method for continuous precision fermentation to produce proteins like BLG more efficiently by making microbes clump together.

dsm-firmenich is presenting an immersive experience at SupplySide Global 2026, focusing on gut health's role in longevity and showcasing its Age Slower solution for healthy aging.

dsm-firmenich will host a webinar on October 13, 2026, focusing on the importance of DHA for prenatal health, supported by evidence and discussing formulation challenges and solutions.

DSM-Firmenich AG provides financial disclosures and filings for investors to understand company performance and strategy.

DSM-Firmenich completed a EUR 540 million share buyback program and plans to cancel over 6.4 million shares by Q1 2027, following a Q2 2026 revenue of EUR 4.664 billion and an EBITDA of EUR 887 million.

DSM-Firmenich's 39.6% year-to-date stock gain leads to an analysis of whether its cash flows support the current share price through a Discounted Cash Flow model.

DSM-Firmenich completed a EUR 540 million share buyback, reducing its share count, while reporting increased quarterly revenue but decreased net profit, with its stock below its 52-week high.

dsm-firmenich completed its –540 million share repurchase program, buying back over 7.1 million shares and planning to cancel 6.4 million shares by early 2027.

DSM-Firmenich completed a 540 million Euro share buyback program.

DSM-Firmenich finalized a EUR540 million share buyback program while the document also details various financial and ESG rating methodologies.

dsm-firmenich completed its •540 million share repurchase program, buying back over 7.1 million shares at an average price of •75.32, with plans to cancel 6.4 million shares by early 2027.

DSM-Firmenich completed a €540 million share buyback, with its stock currently trading at €96.1 amidst mixed valuations.

DSM-Firmenich completed its EUR 540 million share repurchase program on October 1, 2026, planning to cancel 6.5 million shares by Q1 2027, while its stock fell 1.31%.

dsm-firmenich celebrated two new Master Perfumers, Marie Salamagne and Frank Voelkl, and highlighted emerging perfumers during a ceremony in Paris.

DSM-Firmenich stock faced analyst downgrades despite solid Q2 and H1 growth and a reaffirmed positive 2026 outlook.

DSM-Firmenich stock is near its yearly high, with positive Q2 revenue growth and significant share repurchases, and the next earnings update is scheduled for November 3, 2026.

DSM-Firmenich stock increased by 2.37% on September 21, 2026, closing at EUR 94.34, with the company recently repurchasing 260,000 shares.

DSM-Firmenich stock gained 2.37% on September 21, 2026, reaching EUR 94.34, supported by a recent share buyback program and strong fiscal year 2025 sales figures.

DSM-Firmenich stock rose 2.37% to EUR 94.34 as its share buyback program neared completion, with the stock price close to its annual high.